Pharma & Healthcare
Global Biosimilars and Innovative Biological Drugs Market Research Report 2026
- May 01, 26
- ID: 754608
- Pages: 131
- Figures: 127
- Views: 13
This report delivers a comprehensive overview of the global Biosimilars and Innovative Biological Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Biosimilars and Innovative Biological Drugs. The Biosimilars and Innovative Biological Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Biosimilars and Innovative Biological Drugs market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Biosimilars and Innovative Biological Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Biosimilars and Innovative Biological Drugs companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
The report segments the global Biosimilars and Innovative Biological Drugs market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Biosimilars and Innovative Biological Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Biosimilars and Innovative Biological Drugs companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Market by Application
1.3.1 Global Biosimilars and Innovative Biological Drugs Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilars and Innovative Biological Drugs Market Perspective (2021–2032)
2.2 Global Biosimilars and Innovative Biological Drugs Growth Trends by Region
2.2.1 Global Biosimilars and Innovative Biological Drugs Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Biosimilars and Innovative Biological Drugs Historic Market Size by Region (2021–2026)
2.2.3 Biosimilars and Innovative Biological Drugs Forecasted Market Size by Region (2027–2032)
2.3 Biosimilars and Innovative Biological Drugs Market Dynamics
2.3.1 Biosimilars and Innovative Biological Drugs Industry Trends
2.3.2 Biosimilars and Innovative Biological Drugs Market Drivers
2.3.3 Biosimilars and Innovative Biological Drugs Market Challenges
2.3.4 Biosimilars and Innovative Biological Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilars and Innovative Biological Drugs Players by Revenue
3.1.1 Global Top Biosimilars and Innovative Biological Drugs Players by Revenue (2021–2026)
3.1.2 Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Players (2021–2026)
3.2 Global Top Biosimilars and Innovative Biological Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Biosimilars and Innovative Biological Drugs Revenue
3.4 Global Biosimilars and Innovative Biological Drugs Market Concentration Ratio
3.4.1 Global Biosimilars and Innovative Biological Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilars and Innovative Biological Drugs Revenue in 2025
3.5 Global Key Players of Biosimilars and Innovative Biological Drugs Head Offices and Areas Served
3.6 Global Key Players of Biosimilars and Innovative Biological Drugs, Products and Applications
3.7 Global Key Players of Biosimilars and Innovative Biological Drugs, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Biosimilars and Innovative Biological Drugs Breakdown Data by Type
4.1 Global Biosimilars and Innovative Biological Drugs Historic Market Size by Type (2021–2026)
4.2 Global Biosimilars and Innovative Biological Drugs Forecasted Market Size by Type (2027–2032)
5 Biosimilars and Innovative Biological Drugs Breakdown Data by Application
5.1 Global Biosimilars and Innovative Biological Drugs Historic Market Size by Application (2021–2026)
5.2 Global Biosimilars and Innovative Biological Drugs Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Biosimilars and Innovative Biological Drugs Market Size (2021–2032)
6.2 North America Biosimilars and Innovative Biological Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Biosimilars and Innovative Biological Drugs Market Size by Country (2021–2026)
6.4 North America Biosimilars and Innovative Biological Drugs Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilars and Innovative Biological Drugs Market Size (2021–2032)
7.2 Europe Biosimilars and Innovative Biological Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Biosimilars and Innovative Biological Drugs Market Size by Country (2021–2026)
7.4 Europe Biosimilars and Innovative Biological Drugs Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size (2021–2032)
8.2 Asia-Pacific Biosimilars and Innovative Biological Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size by Region (2021–2026)
8.4 Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Biosimilars and Innovative Biological Drugs Market Size (2021–2032)
9.2 Latin America Biosimilars and Innovative Biological Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Biosimilars and Innovative Biological Drugs Market Size by Country (2021–2026)
9.4 Latin America Biosimilars and Innovative Biological Drugs Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size (2021–2032)
10.2 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Country (2021–2026)
10.4 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Biosimilars and Innovative Biological Drugs Introduction
11.1.4 Roche Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Biosimilars and Innovative Biological Drugs Introduction
11.2.4 Amgen Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Biosimilars and Innovative Biological Drugs Introduction
11.3.4 AbbVie Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.3.5 AbbVie Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Biosimilars and Innovative Biological Drugs Introduction
11.4.4 Sanofi Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Biosimilars and Innovative Biological Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Biosimilars and Innovative Biological Drugs Introduction
11.6.4 Pfizer Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Biosimilars and Innovative Biological Drugs Introduction
11.7.4 Novo Nordisk Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Biosimilars and Innovative Biological Drugs Introduction
11.8.4 Eli Lilly Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Biosimilars and Innovative Biological Drugs Introduction
11.9.4 Novartis Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Biosimilars and Innovative Biological Drugs Introduction
11.10.4 Merck Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.10.5 Merck Recent Development
11.11 Biogen
11.11.1 Biogen Company Details
11.11.2 Biogen Business Overview
11.11.3 Biogen Biosimilars and Innovative Biological Drugs Introduction
11.11.4 Biogen Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.11.5 Biogen Recent Development
11.12 Celltrion
11.12.1 Celltrion Company Details
11.12.2 Celltrion Business Overview
11.12.3 Celltrion Biosimilars and Innovative Biological Drugs Introduction
11.12.4 Celltrion Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.12.5 Celltrion Recent Development
11.13 Sobi
11.13.1 Sobi Company Details
11.13.2 Sobi Business Overview
11.13.3 Sobi Biosimilars and Innovative Biological Drugs Introduction
11.13.4 Sobi Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.13.5 Sobi Recent Development
11.14 3SBIO
11.14.1 3SBIO Company Details
11.14.2 3SBIO Business Overview
11.14.3 3SBIO Biosimilars and Innovative Biological Drugs Introduction
11.14.4 3SBIO Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.14.5 3SBIO Recent Development
11.15 Changchun High Tech
11.15.1 Changchun High Tech Company Details
11.15.2 Changchun High Tech Business Overview
11.15.3 Changchun High Tech Biosimilars and Innovative Biological Drugs Introduction
11.15.4 Changchun High Tech Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.15.5 Changchun High Tech Recent Development
11.16 Kanghong Pharma
11.16.1 Kanghong Pharma Company Details
11.16.2 Kanghong Pharma Business Overview
11.16.3 Kanghong Pharma Biosimilars and Innovative Biological Drugs Introduction
11.16.4 Kanghong Pharma Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.16.5 Kanghong Pharma Recent Development
11.17 Innovent Biologics
11.17.1 Innovent Biologics Company Details
11.17.2 Innovent Biologics Business Overview
11.17.3 Innovent Biologics Biosimilars and Innovative Biological Drugs Introduction
11.17.4 Innovent Biologics Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.17.5 Innovent Biologics Recent Development
11.18 Gan&Lee
11.18.1 Gan&Lee Company Details
11.18.2 Gan&Lee Business Overview
11.18.3 Gan&Lee Biosimilars and Innovative Biological Drugs Introduction
11.18.4 Gan&Lee Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.18.5 Gan&Lee Recent Development
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Details
11.19.2 Tonghua Dongbao Business Overview
11.19.3 Tonghua Dongbao Biosimilars and Innovative Biological Drugs Introduction
11.19.4 Tonghua Dongbao Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.19.5 Tonghua Dongbao Recent Development
11.20 United Laboratory
11.20.1 United Laboratory Company Details
11.20.2 United Laboratory Business Overview
11.20.3 United Laboratory Biosimilars and Innovative Biological Drugs Introduction
11.20.4 United Laboratory Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.20.5 United Laboratory Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Market by Application
1.3.1 Global Biosimilars and Innovative Biological Drugs Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilars and Innovative Biological Drugs Market Perspective (2021–2032)
2.2 Global Biosimilars and Innovative Biological Drugs Growth Trends by Region
2.2.1 Global Biosimilars and Innovative Biological Drugs Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Biosimilars and Innovative Biological Drugs Historic Market Size by Region (2021–2026)
2.2.3 Biosimilars and Innovative Biological Drugs Forecasted Market Size by Region (2027–2032)
2.3 Biosimilars and Innovative Biological Drugs Market Dynamics
2.3.1 Biosimilars and Innovative Biological Drugs Industry Trends
2.3.2 Biosimilars and Innovative Biological Drugs Market Drivers
2.3.3 Biosimilars and Innovative Biological Drugs Market Challenges
2.3.4 Biosimilars and Innovative Biological Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilars and Innovative Biological Drugs Players by Revenue
3.1.1 Global Top Biosimilars and Innovative Biological Drugs Players by Revenue (2021–2026)
3.1.2 Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Players (2021–2026)
3.2 Global Top Biosimilars and Innovative Biological Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Biosimilars and Innovative Biological Drugs Revenue
3.4 Global Biosimilars and Innovative Biological Drugs Market Concentration Ratio
3.4.1 Global Biosimilars and Innovative Biological Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilars and Innovative Biological Drugs Revenue in 2025
3.5 Global Key Players of Biosimilars and Innovative Biological Drugs Head Offices and Areas Served
3.6 Global Key Players of Biosimilars and Innovative Biological Drugs, Products and Applications
3.7 Global Key Players of Biosimilars and Innovative Biological Drugs, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Biosimilars and Innovative Biological Drugs Breakdown Data by Type
4.1 Global Biosimilars and Innovative Biological Drugs Historic Market Size by Type (2021–2026)
4.2 Global Biosimilars and Innovative Biological Drugs Forecasted Market Size by Type (2027–2032)
5 Biosimilars and Innovative Biological Drugs Breakdown Data by Application
5.1 Global Biosimilars and Innovative Biological Drugs Historic Market Size by Application (2021–2026)
5.2 Global Biosimilars and Innovative Biological Drugs Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Biosimilars and Innovative Biological Drugs Market Size (2021–2032)
6.2 North America Biosimilars and Innovative Biological Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Biosimilars and Innovative Biological Drugs Market Size by Country (2021–2026)
6.4 North America Biosimilars and Innovative Biological Drugs Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilars and Innovative Biological Drugs Market Size (2021–2032)
7.2 Europe Biosimilars and Innovative Biological Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Biosimilars and Innovative Biological Drugs Market Size by Country (2021–2026)
7.4 Europe Biosimilars and Innovative Biological Drugs Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size (2021–2032)
8.2 Asia-Pacific Biosimilars and Innovative Biological Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size by Region (2021–2026)
8.4 Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Biosimilars and Innovative Biological Drugs Market Size (2021–2032)
9.2 Latin America Biosimilars and Innovative Biological Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Biosimilars and Innovative Biological Drugs Market Size by Country (2021–2026)
9.4 Latin America Biosimilars and Innovative Biological Drugs Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size (2021–2032)
10.2 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Country (2021–2026)
10.4 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Biosimilars and Innovative Biological Drugs Introduction
11.1.4 Roche Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Biosimilars and Innovative Biological Drugs Introduction
11.2.4 Amgen Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Biosimilars and Innovative Biological Drugs Introduction
11.3.4 AbbVie Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.3.5 AbbVie Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Biosimilars and Innovative Biological Drugs Introduction
11.4.4 Sanofi Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Biosimilars and Innovative Biological Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Biosimilars and Innovative Biological Drugs Introduction
11.6.4 Pfizer Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Biosimilars and Innovative Biological Drugs Introduction
11.7.4 Novo Nordisk Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Biosimilars and Innovative Biological Drugs Introduction
11.8.4 Eli Lilly Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Biosimilars and Innovative Biological Drugs Introduction
11.9.4 Novartis Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Biosimilars and Innovative Biological Drugs Introduction
11.10.4 Merck Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.10.5 Merck Recent Development
11.11 Biogen
11.11.1 Biogen Company Details
11.11.2 Biogen Business Overview
11.11.3 Biogen Biosimilars and Innovative Biological Drugs Introduction
11.11.4 Biogen Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.11.5 Biogen Recent Development
11.12 Celltrion
11.12.1 Celltrion Company Details
11.12.2 Celltrion Business Overview
11.12.3 Celltrion Biosimilars and Innovative Biological Drugs Introduction
11.12.4 Celltrion Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.12.5 Celltrion Recent Development
11.13 Sobi
11.13.1 Sobi Company Details
11.13.2 Sobi Business Overview
11.13.3 Sobi Biosimilars and Innovative Biological Drugs Introduction
11.13.4 Sobi Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.13.5 Sobi Recent Development
11.14 3SBIO
11.14.1 3SBIO Company Details
11.14.2 3SBIO Business Overview
11.14.3 3SBIO Biosimilars and Innovative Biological Drugs Introduction
11.14.4 3SBIO Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.14.5 3SBIO Recent Development
11.15 Changchun High Tech
11.15.1 Changchun High Tech Company Details
11.15.2 Changchun High Tech Business Overview
11.15.3 Changchun High Tech Biosimilars and Innovative Biological Drugs Introduction
11.15.4 Changchun High Tech Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.15.5 Changchun High Tech Recent Development
11.16 Kanghong Pharma
11.16.1 Kanghong Pharma Company Details
11.16.2 Kanghong Pharma Business Overview
11.16.3 Kanghong Pharma Biosimilars and Innovative Biological Drugs Introduction
11.16.4 Kanghong Pharma Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.16.5 Kanghong Pharma Recent Development
11.17 Innovent Biologics
11.17.1 Innovent Biologics Company Details
11.17.2 Innovent Biologics Business Overview
11.17.3 Innovent Biologics Biosimilars and Innovative Biological Drugs Introduction
11.17.4 Innovent Biologics Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.17.5 Innovent Biologics Recent Development
11.18 Gan&Lee
11.18.1 Gan&Lee Company Details
11.18.2 Gan&Lee Business Overview
11.18.3 Gan&Lee Biosimilars and Innovative Biological Drugs Introduction
11.18.4 Gan&Lee Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.18.5 Gan&Lee Recent Development
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Details
11.19.2 Tonghua Dongbao Business Overview
11.19.3 Tonghua Dongbao Biosimilars and Innovative Biological Drugs Introduction
11.19.4 Tonghua Dongbao Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.19.5 Tonghua Dongbao Recent Development
11.20 United Laboratory
11.20.1 United Laboratory Company Details
11.20.2 United Laboratory Business Overview
11.20.3 United Laboratory Biosimilars and Innovative Biological Drugs Introduction
11.20.4 United Laboratory Revenue in Biosimilars and Innovative Biological Drugs Business (2021–2026)
11.20.5 United Laboratory Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Interferon
Table 4. Key Players of Insulin
Table 5. Key Players of Vaccines
Table 6. Key Players of Others
Table 7. Global Biosimilars and Innovative Biological Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Biosimilars and Innovative Biological Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 9. Global Biosimilars and Innovative Biological Drugs Market Size by Region (US$ Million), 2021–2026
Table 10. Global Biosimilars and Innovative Biological Drugs Market Share by Region (2021–2026)
Table 11. Global Biosimilars and Innovative Biological Drugs Forecasted Market Size by Region (US$ Million), 2027–2032
Table 12. Global Biosimilars and Innovative Biological Drugs Market Share by Region (2027–2032)
Table 13. Biosimilars and Innovative Biological Drugs Market Trends
Table 14. Biosimilars and Innovative Biological Drugs Market Drivers
Table 15. Biosimilars and Innovative Biological Drugs Market Challenges
Table 16. Biosimilars and Innovative Biological Drugs Market Restraints
Table 17. Global Biosimilars and Innovative Biological Drugs Revenue by Players (US$ Million), 2021–2026
Table 18. Global Biosimilars and Innovative Biological Drugs Market Share by Players (2021–2026)
Table 19. Global Top Biosimilars and Innovative Biological Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Biosimilars and Innovative Biological Drugs Revenue, 2025
Table 20. Ranking of Global Top Biosimilars and Innovative Biological Drugs Companies by Revenue (US$ Million) in 2025
Table 21. Global 5 Largest Players Market Share by Biosimilars and Innovative Biological Drugs Revenue (CR5 and HHI), 2021–2026
Table 22. Global Key Players of Biosimilars and Innovative Biological Drugs, Headquarters and Area Served
Table 23. Global Key Players of Biosimilars and Innovative Biological Drugs, Products and Applications
Table 24. Global Key Players of Biosimilars and Innovative Biological Drugs, Date of General Availability (GA)
Table 25. Mergers and Acquisitions, Expansion Plans
Table 26. Global Biosimilars and Innovative Biological Drugs Market Size by Type (US$ Million), 2021–2026
Table 27. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Type (2021–2026)
Table 28. Global Biosimilars and Innovative Biological Drugs Forecasted Market Size by Type (US$ Million), 2027–2032
Table 29. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Type (2027–2032)
Table 30. Global Biosimilars and Innovative Biological Drugs Market Size by Application (US$ Million), 2021–2026
Table 31. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Application (2021–2026)
Table 32. Global Biosimilars and Innovative Biological Drugs Forecasted Market Size by Application (US$ Million), 2027–2032
Table 33. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Application (2027–2032)
Table 34. North America Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. North America Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2021–2026
Table 36. North America Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2027–2032
Table 37. Europe Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 38. Europe Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2021–2026
Table 39. Europe Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2027–2032
Table 40. Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 41. Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size by Region (US$ Million), 2021–2026
Table 42. Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size by Region (US$ Million), 2027–2032
Table 43. Latin America Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Latin America Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2021–2026
Table 45. Latin America Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2027–2032
Table 46. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 47. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2021–2026
Table 48. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2027–2032
Table 49. Roche Company Details
Table 50. Roche Business Overview
Table 51. Roche Biosimilars and Innovative Biological Drugs Product
Table 52. Roche Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 53. Roche Recent Development
Table 54. Amgen Company Details
Table 55. Amgen Business Overview
Table 56. Amgen Biosimilars and Innovative Biological Drugs Product
Table 57. Amgen Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 58. Amgen Recent Development
Table 59. AbbVie Company Details
Table 60. AbbVie Business Overview
Table 61. AbbVie Biosimilars and Innovative Biological Drugs Product
Table 62. AbbVie Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 63. AbbVie Recent Development
Table 64. Sanofi Company Details
Table 65. Sanofi Business Overview
Table 66. Sanofi Biosimilars and Innovative Biological Drugs Product
Table 67. Sanofi Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 68. Sanofi Recent Development
Table 69. Johnson & Johnson Company Details
Table 70. Johnson & Johnson Business Overview
Table 71. Johnson & Johnson Biosimilars and Innovative Biological Drugs Product
Table 72. Johnson & Johnson Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 73. Johnson & Johnson Recent Development
Table 74. Pfizer Company Details
Table 75. Pfizer Business Overview
Table 76. Pfizer Biosimilars and Innovative Biological Drugs Product
Table 77. Pfizer Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 78. Pfizer Recent Development
Table 79. Novo Nordisk Company Details
Table 80. Novo Nordisk Business Overview
Table 81. Novo Nordisk Biosimilars and Innovative Biological Drugs Product
Table 82. Novo Nordisk Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 83. Novo Nordisk Recent Development
Table 84. Eli Lilly Company Details
Table 85. Eli Lilly Business Overview
Table 86. Eli Lilly Biosimilars and Innovative Biological Drugs Product
Table 87. Eli Lilly Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 88. Eli Lilly Recent Development
Table 89. Novartis Company Details
Table 90. Novartis Business Overview
Table 91. Novartis Biosimilars and Innovative Biological Drugs Product
Table 92. Novartis Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 93. Novartis Recent Development
Table 94. Merck Company Details
Table 95. Merck Business Overview
Table 96. Merck Biosimilars and Innovative Biological Drugs Product
Table 97. Merck Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 98. Merck Recent Development
Table 99. Biogen Company Details
Table 100. Biogen Business Overview
Table 101. Biogen Biosimilars and Innovative Biological Drugs Product
Table 102. Biogen Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 103. Biogen Recent Development
Table 104. Celltrion Company Details
Table 105. Celltrion Business Overview
Table 106. Celltrion Biosimilars and Innovative Biological Drugs Product
Table 107. Celltrion Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 108. Celltrion Recent Development
Table 109. Sobi Company Details
Table 110. Sobi Business Overview
Table 111. Sobi Biosimilars and Innovative Biological Drugs Product
Table 112. Sobi Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 113. Sobi Recent Development
Table 114. 3SBIO Company Details
Table 115. 3SBIO Business Overview
Table 116. 3SBIO Biosimilars and Innovative Biological Drugs Product
Table 117. 3SBIO Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 118. 3SBIO Recent Development
Table 119. Changchun High Tech Company Details
Table 120. Changchun High Tech Business Overview
Table 121. Changchun High Tech Biosimilars and Innovative Biological Drugs Product
Table 122. Changchun High Tech Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 123. Changchun High Tech Recent Development
Table 124. Kanghong Pharma Company Details
Table 125. Kanghong Pharma Business Overview
Table 126. Kanghong Pharma Biosimilars and Innovative Biological Drugs Product
Table 127. Kanghong Pharma Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 128. Kanghong Pharma Recent Development
Table 129. Innovent Biologics Company Details
Table 130. Innovent Biologics Business Overview
Table 131. Innovent Biologics Biosimilars and Innovative Biological Drugs Product
Table 132. Innovent Biologics Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 133. Innovent Biologics Recent Development
Table 134. Gan&Lee Company Details
Table 135. Gan&Lee Business Overview
Table 136. Gan&Lee Biosimilars and Innovative Biological Drugs Product
Table 137. Gan&Lee Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 138. Gan&Lee Recent Development
Table 139. Tonghua Dongbao Company Details
Table 140. Tonghua Dongbao Business Overview
Table 141. Tonghua Dongbao Biosimilars and Innovative Biological Drugs Product
Table 142. Tonghua Dongbao Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 143. Tonghua Dongbao Recent Development
Table 144. United Laboratory Company Details
Table 145. United Laboratory Business Overview
Table 146. United Laboratory Biosimilars and Innovative Biological Drugs Product
Table 147. United Laboratory Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 148. United Laboratory Recent Development
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
Table 152. Authors List of This Report
List of Figures
Figure 1. Biosimilars and Innovative Biological Drugs Picture
Figure 2. Global Biosimilars and Innovative Biological Drugs Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Biosimilars and Innovative Biological Drugs Market Share by Type: 2025 vs 2032
Figure 4. Monoclonal Antibodies Features
Figure 5. Interferon Features
Figure 6. Insulin Features
Figure 7. Vaccines Features
Figure 8. Others Features
Figure 9. Global Biosimilars and Innovative Biological Drugs Market Size by Application (US$ Million), 2021–2032
Figure 10. Global Biosimilars and Innovative Biological Drugs Market Share by Application: 2025 vs 2032
Figure 11. Hospital Case Studies
Figure 12. Retail Pharmacy Case Studies
Figure 13. Other Case Studies
Figure 14. Biosimilars and Innovative Biological Drugs Report Years Considered
Figure 15. Global Biosimilars and Innovative Biological Drugs Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 16. Global Biosimilars and Innovative Biological Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Biosimilars and Innovative Biological Drugs Market Share by Region: 2025 vs 2032
Figure 18. Global Biosimilars and Innovative Biological Drugs Market Share by Players in 2025
Figure 19. Global Biosimilars and Innovative Biological Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by Biosimilars and Innovative Biological Drugs Revenue in 2025
Figure 21. North America Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. North America Biosimilars and Innovative Biological Drugs Market Share by Country (2021–2032)
Figure 23. United States Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Canada Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Biosimilars and Innovative Biological Drugs Market Share by Country (2021–2032)
Figure 27. Germany Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. France Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. U.K. Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Italy Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Russia Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Ireland Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Biosimilars and Innovative Biological Drugs Market Share by Region (2021–2032)
Figure 35. China Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Japan Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. South Korea Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Southeast Asia Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. India Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Australia & New Zealand Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Biosimilars and Innovative Biological Drugs Market Share by Country (2021–2032)
Figure 43. Mexico Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Brazil Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Share by Country (2021–2032)
Figure 47. Israel Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Saudi Arabia Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. UAE Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Roche Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 51. Amgen Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 52. AbbVie Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 53. Sanofi Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 54. Johnson & Johnson Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 55. Pfizer Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 56. Novo Nordisk Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 57. Eli Lilly Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 58. Novartis Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 59. Merck Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 60. Biogen Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 61. Celltrion Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 62. Sobi Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 63. 3SBIO Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 64. Changchun High Tech Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 65. Kanghong Pharma Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 66. Innovent Biologics Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 67. Gan&Lee Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 68. Tonghua Dongbao Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 69. United Laboratory Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Table 1. Global Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Interferon
Table 4. Key Players of Insulin
Table 5. Key Players of Vaccines
Table 6. Key Players of Others
Table 7. Global Biosimilars and Innovative Biological Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Biosimilars and Innovative Biological Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 9. Global Biosimilars and Innovative Biological Drugs Market Size by Region (US$ Million), 2021–2026
Table 10. Global Biosimilars and Innovative Biological Drugs Market Share by Region (2021–2026)
Table 11. Global Biosimilars and Innovative Biological Drugs Forecasted Market Size by Region (US$ Million), 2027–2032
Table 12. Global Biosimilars and Innovative Biological Drugs Market Share by Region (2027–2032)
Table 13. Biosimilars and Innovative Biological Drugs Market Trends
Table 14. Biosimilars and Innovative Biological Drugs Market Drivers
Table 15. Biosimilars and Innovative Biological Drugs Market Challenges
Table 16. Biosimilars and Innovative Biological Drugs Market Restraints
Table 17. Global Biosimilars and Innovative Biological Drugs Revenue by Players (US$ Million), 2021–2026
Table 18. Global Biosimilars and Innovative Biological Drugs Market Share by Players (2021–2026)
Table 19. Global Top Biosimilars and Innovative Biological Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Biosimilars and Innovative Biological Drugs Revenue, 2025
Table 20. Ranking of Global Top Biosimilars and Innovative Biological Drugs Companies by Revenue (US$ Million) in 2025
Table 21. Global 5 Largest Players Market Share by Biosimilars and Innovative Biological Drugs Revenue (CR5 and HHI), 2021–2026
Table 22. Global Key Players of Biosimilars and Innovative Biological Drugs, Headquarters and Area Served
Table 23. Global Key Players of Biosimilars and Innovative Biological Drugs, Products and Applications
Table 24. Global Key Players of Biosimilars and Innovative Biological Drugs, Date of General Availability (GA)
Table 25. Mergers and Acquisitions, Expansion Plans
Table 26. Global Biosimilars and Innovative Biological Drugs Market Size by Type (US$ Million), 2021–2026
Table 27. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Type (2021–2026)
Table 28. Global Biosimilars and Innovative Biological Drugs Forecasted Market Size by Type (US$ Million), 2027–2032
Table 29. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Type (2027–2032)
Table 30. Global Biosimilars and Innovative Biological Drugs Market Size by Application (US$ Million), 2021–2026
Table 31. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Application (2021–2026)
Table 32. Global Biosimilars and Innovative Biological Drugs Forecasted Market Size by Application (US$ Million), 2027–2032
Table 33. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Application (2027–2032)
Table 34. North America Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. North America Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2021–2026
Table 36. North America Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2027–2032
Table 37. Europe Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 38. Europe Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2021–2026
Table 39. Europe Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2027–2032
Table 40. Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 41. Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size by Region (US$ Million), 2021–2026
Table 42. Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size by Region (US$ Million), 2027–2032
Table 43. Latin America Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Latin America Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2021–2026
Table 45. Latin America Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2027–2032
Table 46. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 47. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2021–2026
Table 48. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Country (US$ Million), 2027–2032
Table 49. Roche Company Details
Table 50. Roche Business Overview
Table 51. Roche Biosimilars and Innovative Biological Drugs Product
Table 52. Roche Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 53. Roche Recent Development
Table 54. Amgen Company Details
Table 55. Amgen Business Overview
Table 56. Amgen Biosimilars and Innovative Biological Drugs Product
Table 57. Amgen Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 58. Amgen Recent Development
Table 59. AbbVie Company Details
Table 60. AbbVie Business Overview
Table 61. AbbVie Biosimilars and Innovative Biological Drugs Product
Table 62. AbbVie Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 63. AbbVie Recent Development
Table 64. Sanofi Company Details
Table 65. Sanofi Business Overview
Table 66. Sanofi Biosimilars and Innovative Biological Drugs Product
Table 67. Sanofi Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 68. Sanofi Recent Development
Table 69. Johnson & Johnson Company Details
Table 70. Johnson & Johnson Business Overview
Table 71. Johnson & Johnson Biosimilars and Innovative Biological Drugs Product
Table 72. Johnson & Johnson Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 73. Johnson & Johnson Recent Development
Table 74. Pfizer Company Details
Table 75. Pfizer Business Overview
Table 76. Pfizer Biosimilars and Innovative Biological Drugs Product
Table 77. Pfizer Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 78. Pfizer Recent Development
Table 79. Novo Nordisk Company Details
Table 80. Novo Nordisk Business Overview
Table 81. Novo Nordisk Biosimilars and Innovative Biological Drugs Product
Table 82. Novo Nordisk Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 83. Novo Nordisk Recent Development
Table 84. Eli Lilly Company Details
Table 85. Eli Lilly Business Overview
Table 86. Eli Lilly Biosimilars and Innovative Biological Drugs Product
Table 87. Eli Lilly Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 88. Eli Lilly Recent Development
Table 89. Novartis Company Details
Table 90. Novartis Business Overview
Table 91. Novartis Biosimilars and Innovative Biological Drugs Product
Table 92. Novartis Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 93. Novartis Recent Development
Table 94. Merck Company Details
Table 95. Merck Business Overview
Table 96. Merck Biosimilars and Innovative Biological Drugs Product
Table 97. Merck Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 98. Merck Recent Development
Table 99. Biogen Company Details
Table 100. Biogen Business Overview
Table 101. Biogen Biosimilars and Innovative Biological Drugs Product
Table 102. Biogen Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 103. Biogen Recent Development
Table 104. Celltrion Company Details
Table 105. Celltrion Business Overview
Table 106. Celltrion Biosimilars and Innovative Biological Drugs Product
Table 107. Celltrion Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 108. Celltrion Recent Development
Table 109. Sobi Company Details
Table 110. Sobi Business Overview
Table 111. Sobi Biosimilars and Innovative Biological Drugs Product
Table 112. Sobi Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 113. Sobi Recent Development
Table 114. 3SBIO Company Details
Table 115. 3SBIO Business Overview
Table 116. 3SBIO Biosimilars and Innovative Biological Drugs Product
Table 117. 3SBIO Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 118. 3SBIO Recent Development
Table 119. Changchun High Tech Company Details
Table 120. Changchun High Tech Business Overview
Table 121. Changchun High Tech Biosimilars and Innovative Biological Drugs Product
Table 122. Changchun High Tech Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 123. Changchun High Tech Recent Development
Table 124. Kanghong Pharma Company Details
Table 125. Kanghong Pharma Business Overview
Table 126. Kanghong Pharma Biosimilars and Innovative Biological Drugs Product
Table 127. Kanghong Pharma Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 128. Kanghong Pharma Recent Development
Table 129. Innovent Biologics Company Details
Table 130. Innovent Biologics Business Overview
Table 131. Innovent Biologics Biosimilars and Innovative Biological Drugs Product
Table 132. Innovent Biologics Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 133. Innovent Biologics Recent Development
Table 134. Gan&Lee Company Details
Table 135. Gan&Lee Business Overview
Table 136. Gan&Lee Biosimilars and Innovative Biological Drugs Product
Table 137. Gan&Lee Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 138. Gan&Lee Recent Development
Table 139. Tonghua Dongbao Company Details
Table 140. Tonghua Dongbao Business Overview
Table 141. Tonghua Dongbao Biosimilars and Innovative Biological Drugs Product
Table 142. Tonghua Dongbao Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 143. Tonghua Dongbao Recent Development
Table 144. United Laboratory Company Details
Table 145. United Laboratory Business Overview
Table 146. United Laboratory Biosimilars and Innovative Biological Drugs Product
Table 147. United Laboratory Revenue in Biosimilars and Innovative Biological Drugs Business (US$ Million), 2021–2026
Table 148. United Laboratory Recent Development
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
Table 152. Authors List of This Report
List of Figures
Figure 1. Biosimilars and Innovative Biological Drugs Picture
Figure 2. Global Biosimilars and Innovative Biological Drugs Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Biosimilars and Innovative Biological Drugs Market Share by Type: 2025 vs 2032
Figure 4. Monoclonal Antibodies Features
Figure 5. Interferon Features
Figure 6. Insulin Features
Figure 7. Vaccines Features
Figure 8. Others Features
Figure 9. Global Biosimilars and Innovative Biological Drugs Market Size by Application (US$ Million), 2021–2032
Figure 10. Global Biosimilars and Innovative Biological Drugs Market Share by Application: 2025 vs 2032
Figure 11. Hospital Case Studies
Figure 12. Retail Pharmacy Case Studies
Figure 13. Other Case Studies
Figure 14. Biosimilars and Innovative Biological Drugs Report Years Considered
Figure 15. Global Biosimilars and Innovative Biological Drugs Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 16. Global Biosimilars and Innovative Biological Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Biosimilars and Innovative Biological Drugs Market Share by Region: 2025 vs 2032
Figure 18. Global Biosimilars and Innovative Biological Drugs Market Share by Players in 2025
Figure 19. Global Biosimilars and Innovative Biological Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by Biosimilars and Innovative Biological Drugs Revenue in 2025
Figure 21. North America Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. North America Biosimilars and Innovative Biological Drugs Market Share by Country (2021–2032)
Figure 23. United States Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Canada Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Biosimilars and Innovative Biological Drugs Market Share by Country (2021–2032)
Figure 27. Germany Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. France Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. U.K. Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Italy Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Russia Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Ireland Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Biosimilars and Innovative Biological Drugs Market Share by Region (2021–2032)
Figure 35. China Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Japan Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. South Korea Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Southeast Asia Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. India Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Australia & New Zealand Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Biosimilars and Innovative Biological Drugs Market Share by Country (2021–2032)
Figure 43. Mexico Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Brazil Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Share by Country (2021–2032)
Figure 47. Israel Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Saudi Arabia Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. UAE Biosimilars and Innovative Biological Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Roche Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 51. Amgen Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 52. AbbVie Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 53. Sanofi Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 54. Johnson & Johnson Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 55. Pfizer Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 56. Novo Nordisk Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 57. Eli Lilly Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 58. Novartis Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 59. Merck Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 60. Biogen Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 61. Celltrion Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 62. Sobi Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 63. 3SBIO Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 64. Changchun High Tech Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 65. Kanghong Pharma Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 66. Innovent Biologics Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 67. Gan&Lee Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 68. Tonghua Dongbao Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 69. United Laboratory Revenue Growth Rate in Biosimilars and Innovative Biological Drugs Business (2021–2026)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Natural Cocoa Extracts Market Research Report 2026
May 01, 26
Global Semiconductor Switched Mode Power Supply Market Research Report 2026
May 01, 26
Global Silicone Coated Spandrel Glass Market Research Report 2026
May 01, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232